Mylan Knocks Ranbaxy's Exclusivity Right For Valsartan

Law360, New York (October 2, 2012, 10:29 PM EDT) -- Mylan Pharmaceuticals Inc. on Tuesday hit the U.S. Food and Drug Administration with a lawsuit objecting to its award of a 180-day exclusivity period to Ranbaxy Pharmaceuticals Inc. for the marketing of a generic version of hypertension drug valsartan.

Mylan argues Ranbaxy forfeited its eligibility for the exclusivity period when it failed to obtain tentative approval of its abbreviated new drug application within 30 months after it was filed, as required by federal law. The drugmaker is asking the court to vacate the FDA's decision to...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

MYLAN LABORATORIES LIMITED et al v. FOOD AND DRUG ADMINISTRATION et al


Case Number

1:12-cv-01637

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

John D. Bates

Date Filed

October 2, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.